A positive net benefit for probability thresholds between 1% and 100% compared with screening as if all of the JDM patients would be detected with anti-MDA5 or screening as if none of the JDM patients were screened in all the two models. This evidence concerns the gene IFIH1 and juvenile dermatomyositis.